2190 — Zylox-Tonbridge Medical Technology Co Income Statement
0.000.00%
Last trade - 00:00
- HK$6.15bn
- HK$4.57bn
- CNY527.75m
- 35
- 12
- 43
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.92 | 27.6 | 178 | 334 | 528 |
Cost of Revenue | |||||
Gross Profit | 1.19 | 16.3 | 132 | 253 | 385 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 70.6 | 128 | 390 | 542 | 684 |
Operating Profit | -65.7 | -100 | -212 | -208 | -157 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -66.6 | -100 | -200 | -114 | -78.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -66.6 | -100 | -200 | -114 | -78.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -66.6 | -100 | -200 | -114 | -78.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -66.6 | -100 | -200 | -114 | -78.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.201 | -0.302 | -0.601 | -0.315 | -0.239 |